avapro has been researched along with Thyrotoxicosis in 1 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Thyrotoxicosis: A hypermetabolic syndrome caused by excess THYROID HORMONES which may come from endogenous or exogenous sources. The endogenous source of hormone may be thyroid HYPERPLASIA; THYROID NEOPLASMS; or hormone-producing extrathyroidal tissue. Thyrotoxicosis is characterized by NERVOUSNESS; TACHYCARDIA; FATIGUE; WEIGHT LOSS; heat intolerance; and excessive SWEATING.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A rat model of thyrotoxicosis was established by daily intraperitoneal injections of L-thyroxine (T(4), 100 μg/kg) for 4 weeks." | 3.78 | Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy. ( Cho, KI; Choi, BG; Jeon, YK; Kang, JH; Kim, BH; Kim, IJ; Kim, JY; Kim, SJ; Kim, SM; Kim, SS; Kim, YK, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, BH | 1 |
| Cho, KI | 1 |
| Kim, SM | 1 |
| Kim, JY | 1 |
| Choi, BG | 1 |
| Kang, JH | 1 |
| Jeon, YK | 1 |
| Kim, SS | 1 |
| Kim, SJ | 1 |
| Kim, YK | 1 |
| Kim, IJ | 1 |
1 other study available for avapro and Thyrotoxicosis
| Article | Year |
|---|---|
Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomyopathies; Echocardiogr | 2012 |